4D Molecular Therapeutics(FDMT)
$12.99+0.53 (+4.25%)
FDMT
4D Molecular Therapeutics financials statements
$12.99
At close:+0.53 (+4.25%)
Want to see FDMT full AI Analyst Report?
4D Molecular Therapeutics (FDMT) Ratios
534 Followers
4D Molecular Therapeutics Ratios
FDMT's free cash flow for Q2 2026 was $-70.05M. For the 2026 fiscal year, FDMT's free cash flow was decreased by $-55.00K and operating cash flow was $-70.00M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 9.39 | 14.92 | 15.65 | 14.02 | 15.69 |
| Quick Ratio | 9.39 | 14.92 | 15.65 | 14.02 | 15.69 |
| Cash Ratio | 1.37 | 5.12 | 13.14 | 3.33 | 9.36 |
| Solvency Ratio | -2.17 | -3.10 | -3.01 | -3.44 | -2.03 |
| Operating Cash Flow Ratio | -2.48 | -4.62 | -4.00 | -5.51 | -4.23 |
| Short-Term Operating Cash Flow Coverage | 0.00 | 0.00 | 0.00 | -32.65 | 0.00 |
| Net Current Asset Value | $ 352.09M | $ 385.15M | $ 264.53M | $ 190.00M | $ 221.90M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.04 | 0.04 | 0.04 | 0.06 | 0.05 |
| Debt-to-Equity Ratio | 0.04 | 0.05 | 0.05 | 0.07 | 0.05 |
| Debt-to-Capital Ratio | 0.04 | 0.05 | 0.05 | 0.07 | 0.05 |
| Long-Term Debt-to-Capital Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financial Leverage Ratio | 1.12 | 1.10 | 1.10 | 1.13 | 1.11 |
| Debt Service Coverage Ratio | 0.00 | 0.00 | 0.00 | -40.54 | 0.00 |
| Interest Coverage Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Debt to Market Cap | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Debt Per Share | 0.37 | 0.46 | 0.37 | 0.50 | 0.59 |
| Net Debt to EBITDA | 0.29 | 0.81 | 2.16 | 0.34 | 1.96 |
| Profitability Margins | |||||
| Gross Profit Margin | 91.05% | -381789.19% | -368.54% | -2464.81% | -240.17% |
| EBIT Margin | -164.43% | -434778.38% | -544.65% | -3516.52% | -395.46% |
| EBITDA Margin | -155.48% | -416656.76% | -524.36% | -3439.73% | -387.02% |
| Operating Profit Margin | -187.24% | -507678.38% | -544.65% | -3516.52% | -395.46% |
| Pretax Profit Margin | -164.43% | -434778.38% | -486.59% | -3435.41% | -395.37% |
| Net Profit Margin | -164.43% | -434778.38% | -486.59% | -3435.41% | -395.37% |
| Continuous Operations Profit Margin | -164.43% | -434778.38% | -486.59% | -3435.41% | -395.37% |
| Net Income Per EBT | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
| EBT Per EBIT | 87.82% | 85.64% | 89.34% | 97.69% | 99.98% |
| Return on Assets (ROA) | -24.72% | -28.71% | -29.67% | -41.05% | -20.18% |
| Return on Equity (ROE) | -27.71% | -31.51% | -32.76% | -46.47% | -22.35% |
| Return on Capital Employed (ROCE) | -30.52% | -35.36% | -35.17% | -44.71% | -21.16% |
| Return on Invested Capital (ROIC) | -30.20% | -34.99% | -34.83% | -44.23% | -21.08% |
| Return on Tangible Assets | -24.72% | -28.71% | -29.67% | -41.05% | -20.18% |
| Earnings Yield | -32.25% | -53.54% | -12.72% | -14.96% | -11.72% |
| Efficiency Ratios | |||||
| Receivables Turnover | 0.00 | 0.00 | 0.00 | 4.47 | 383.79 |
| Payables Turnover | 0.68 | 32.22 | 27.62 | 24.16 | 12.88 |
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Fixed Asset Turnover | 2.58 | 0.00 | 0.65 | 0.09 | 0.62 |
| Asset Turnover | 0.15 | 0.00 | 0.06 | 0.01 | 0.05 |
| Working Capital Turnover Ratio | 0.22 | 0.00 | 0.09 | 0.01 | 0.07 |
| Cash Conversion Cycle | -534.17 | -11.33 | -13.21 | 66.55 | -27.39 |
| Days of Sales Outstanding | 0.00 | 0.00 | 0.00 | 81.66 | 0.95 |
| Days of Inventory Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Payables Outstanding | 534.17 | 11.33 | 13.21 | 15.11 | 28.34 |
| Operating Cycle | 0.00 | 0.00 | 0.00 | 81.66 | 0.95 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -1.88 | -2.49 | -1.94 | -2.68 | -2.49 |
| Free Cash Flow Per Share | -1.89 | -2.57 | -2.01 | -3.04 | -2.82 |
| Dividend Paid and CapEx Coverage Ratio | -203.51 | -35.55 | -27.35 | -7.51 | -7.59 |
| Capital Expenditure Coverage Ratio | -203.51 | -35.55 | -27.35 | -7.51 | -7.59 |
| Operating Cash Flow Coverage Ratio | -5.09 | -5.47 | -5.17 | -5.38 | -4.20 |
| Operating Cash Flow to Sales Ratio | -1.28 | -3637.43 | -3.66 | -27.70 | -3.83 |
| Free Cash Flow Yield | -25.23% | -46.05% | -9.91% | -13.67% | -12.86% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -3.10 | -1.87 | -7.86 | -6.68 | -8.53 |
| Price-to-Sales (P/S) Ratio | 5.10 | 8120.72 | 38.26 | 229.63 | 33.73 |
| Price-to-Book (P/B) Ratio | 0.86 | 0.59 | 2.58 | 3.11 | 1.91 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -3.96 | -2.17 | -10.09 | -7.32 | -7.78 |
| Price-to-Operating Cash Flow Ratio | -3.98 | -2.23 | -10.46 | -8.29 | -8.80 |
| Price-to-Earnings Growth (PEG) Ratio | 0.16 | -0.12 | 0.45 | -0.25 | -0.53 |
| Enterprise Value Multiple | -2.99 | -1.14 | -5.14 | -6.34 | -6.76 |
| Enterprise Value | 395.65M | 175.74M | 558.34M | 682.29M | 471.85M |
| EV to EBITDA | -2.99 | -1.14 | -5.14 | -6.34 | -6.76 |
| EV to Sales | 4.64 | 4749.64 | 26.94 | 218.05 | 26.16 |
| EV to Free Cash Flow | -3.61 | -1.27 | -7.11 | -6.95 | -6.03 |
| EV to Operating Cash Flow | -3.63 | -1.31 | -7.37 | -7.87 | -6.83 |
| Tangible Book Value Per Share | 8.73 | 9.47 | 7.87 | 7.15 | 11.51 |
| Shareholders’ Equity Per Share | 8.73 | 9.47 | 7.87 | 7.15 | 11.51 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Revenue Per Share | 1.47 | 0.00 | 0.53 | 0.10 | 0.65 |
| Net Income Per Share | -2.42 | -2.98 | -2.58 | -3.32 | -2.57 |
| Tax Burden | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
| Interest Burden | 1.00 | 1.00 | 0.89 | 0.98 | 1.00 |
| Research & Development to Revenue | 2.30 | 3818.89 | 4.69 | 25.65 | 3.40 |
| SG&A to Revenue | 0.58 | 1258.89 | 1.76 | 10.52 | 1.55 |
| Stock-Based Compensation to Revenue | 0.26 | 705.84 | 0.95 | 5.47 | 0.76 |
| Income Quality | 0.78 | 0.84 | 0.75 | 0.81 | 0.97 |
Currency in USD
